Brennan Edward J. 4

What Happened

• Brennan Edward J., Chief Scientific Officer of Medicus Pharma Ltd. (MDCX), was reported on a Form 4 to have received an award/other acquisition of 25,000 shares on March 30, 2026. The filing lists the acquisition price as $0.00 (derivative award), so no cash was paid in the transaction.

Key Details

• Transaction date: 2026-03-30; Filing date: 2026-04-01 (filed two days after the transaction; appears timely).
• Transaction type/code: Award/Grant (A) recorded as a derivative acquisition.
• Shares acquired: 25,000; Price per share reported: $0.00; Total cash paid: $0.
• Shares owned after transaction: not specified in the summary information provided in this prompt (check the full Form 4 for post-transaction holdings).
• No 10b5-1 plan, tax withholding, or other footnotes were provided here—review the full filing for any vesting or restriction details.

Context

• This was an insider award (compensation) rather than an open-market purchase or sale. Such awards are commonly used for executive compensation and are often subject to vesting or other restrictions; they do not necessarily indicate an immediate personal cash investment or short-term trading intent. For full details (vesting schedule, restrictions, or total holdings), consult the full Form 4 filing (Accession: 0000950142-26-001024).